Provided by Tiger Trade Technology Pte. Ltd.

Spruce Biosciences, Inc.

53.86
-0.3000-0.55%
Post-market: 53.860.00000.00%19:30 EDT
Volume:135.27K
Turnover:7.40M
Market Cap:154.79M
PE:-1.40
High:57.11
Open:56.22
Low:53.28
Close:54.16
52wk High:240.00
52wk Low:7.26
Shares:2.87M
Float Shares:2.29M
Volume Ratio:1.30
T/O Rate:5.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-38.4300
EPS(LYR):-50.8298
ROE:-105.98%
ROA:-40.03%
PB:1.85
PE(LYR):-1.06

Loading ...

Spruce Biosciences management to meet virtually with B. Riley

TIPRANKS
·
Yesterday

Spruce Biosciences Initiated at Buy by Lake Street

Dow Jones
·
Yesterday

Spruce Biosciences initiated with a Buy at Lake Street

TIPRANKS
·
Yesterday

Spruce Biosciences CEO to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 09

Spruce Biosciences announces launch of MPS3BStudy.com

TIPRANKS
·
Aug 26

Spruce Biosciences, - Biosciences Launches Mps3bstudy.com for Mps Iiib Families and Caregivers

THOMSON REUTERS
·
Aug 26

Spruce Biosciences, - Ta-Ert Eap and Transform Study Expected to Initiate in Q4 2026

THOMSON REUTERS
·
Aug 26

Spruce Biosciences Launches Site for Planned TA-ERT Sanfilippo B Confirmatory Trial in Q4 2026

Reuters
·
Aug 26

Oppenheimer Sticks to Its Buy Rating for Spruce Biosciences (SPRB)

TIPRANKS
·
Aug 25

Spruce Biosciences Targets Q4 2026 BLA Filing for TA-ERT in Sanfilippo Syndrome Type B After FDA Meetings

Reuters
·
Aug 24

Spruce Biosciences, - Co and FDA Aligned on Confirmatory Study Design; Initiation May Occur During Bla Review

THOMSON REUTERS
·
Aug 24

Spruce Biosciences Announces Positive Pre-Bla Meetings with FDA and Confirms Bla Submission for Ta-Ert on Track for Q4 2026

THOMSON REUTERS
·
Aug 24

Spruce Biosciences, - FDA and Spruce Aligned on Content and Format of Planned Bla

THOMSON REUTERS
·
Aug 24

Spruce Biosciences, - Pursuing Accelerated Approval Pathway Based on Reduction of Csf Hs-Nre

THOMSON REUTERS
·
Aug 24

Spruce Biosciences, - FDA Finds Spruce's Comparability Strategies Reasonable Following Technology Transfer

THOMSON REUTERS
·
Aug 24

Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (BKD) and Spruce Biosciences (SPRB)

TIPRANKS
·
Aug 21

Longeveron Q2 Net Loss Widens on Higher Legal, Clinical Trial Costs

Reuters
·
Aug 13

Spruce Biosciences Q2 FY26 Net Loss Widens to $16.23 Million; R&D Expenses Rise to $12.16 Million

Reuters
·
Aug 12

Spruce Biosciences, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Spruce Biosciences Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 12